Cargando…

Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease

PURPOSE OF REVIEW: Implementation of intensive LDL cholesterol (LDL-C) lowering strategies and recognition of the role of triglyceride-rich lipoproteins (TRL) in atherosclerosis has prompted re-evaluation of the suitability of current lipid profile measurements for future clinical practice. RECENT F...

Descripción completa

Detalles Bibliográficos
Autor principal:	Packard, Chris J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Statin Drugs (R. Ceska, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983627/ https://www.ncbi.nlm.nih.gov/pubmed/35175548 http://dx.doi.org/10.1007/s11883-022-00994-z

Ejemplares similares

LDL Apheresis and Lp (a) Apheresis: A Clinician’s Perspective
por: Kayikcioglu, Meral
Publicado: (2021)

The Role of High-Density Lipoprotein Cholesterol in 2022
por: Sirtori, Cesare R., et al.
Publicado: (2022)

Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease
por: Martin, Anna, et al.
Publicado: (2022)

The Knowns and Unknowns of Contemporary Statin Therapy for Familial Hypercholesterolemia
por: Pang, Jing, et al.
Publicado: (2020)

Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?
por: Fruchart, Jean-Charles, et al.
Publicado: (2021)

Lipid Lowering Drugs: Present Status and Future Developments
por: Ruscica, Massimiliano, et al.
Publicado: (2021)

Current Approach to the Diagnosis and Treatment of Heterozygote and Homozygous FH Children and Adolescents
por: Cohen, Hofit, et al.
Publicado: (2021)

PCSK9 Inhibitors in Real-world Practice: Analysis of Data from 314 Patients and 2 Years of Experience in a Center of Preventive Cardiology
por: Altschmiedová, Tereza, et al.
Publicado: (2022)

An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial
por: Lorgelly, Paula K., et al.
Publicado: (2010)

A Review of the Rationale for Additional Therapeutic Interventions to Attain Lower LDL-C When Statin Therapy Is Not Enough
por: Shanes, Jeffrey G.
Publicado: (2011)

Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence
por: Lee, Matthew M. Y., et al.
Publicado: (2019)

Role of Statin Therapy in Primary Prevention of Cardiovascular Disease in Elderly Patients
por: Strandberg, Timo E.
Publicado: (2019)

Statin Intolerance: the Clinician’s Perspective
por: Stulc, Tomáš, et al.
Publicado: (2015)

Current Role of Lipoprotein Apheresis
por: Thompson, Gilbert, et al.
Publicado: (2019)

Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD
por: Taskinen, Marja-Riitta, et al.
Publicado: (2019)

The Role of Triglyceride-rich Lipoproteins and Their Remnants in Atherosclerotic Cardiovascular Disease
por: Gabani, Mohanad, et al.
Publicado: (2023)

Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study
por: Björnson, Elias, et al.
Publicado: (2023)

Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases
por: Yamashita, Shizuya, et al.
Publicado: (2020)

Triglyceride-Rich Lipoproteins and Their Remnants as Silent Promoters of Atherosclerotic Cardiovascular Disease and Other Metabolic Disorders: A Review
por: Sascău, Radu, et al.
Publicado: (2021)

Cholesterol Remnants, Triglyceride-Rich Lipoproteins and Cardiovascular Risk
por: Baratta, Francesco, et al.
Publicado: (2023)

Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy?
por: Dallinga-Thie, Geesje M., et al.
Publicado: (2016)

Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society
por: Ginsberg, Henry N, et al.
Publicado: (2021)

Triglyceride-Rich Lipoproteins and Remnant Cholesterol in Cardiovascular Disease
por: Heo, Ji Hye, et al.
Publicado: (2023)

High Levels of Remnant Lipoprotein Cholesterol Is a Risk Factor for Large Artery Atherosclerotic Stroke
por: Kim, Jeong-Yeon, et al.
Publicado: (2011)

Remnant cholesterol and atherosclerotic cardiovascular disease: Metabolism, mechanism, evidence, and treatment
por: Wang, Kexin, et al.
Publicado: (2022)

Measurement of Serum Low Density Lipoprotein Cholesterol and Triglyceride-Rich Remnant Cholesterol as Independent Predictors of Atherosclerotic Cardiovascular Disease: Possibilities and Limitations
por: Lütjohann, Dieter, et al.
Publicado: (2023)

Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins
por: Visser, Jolien, et al.
Publicado: (2022)

Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life
por: Robinson, Jennifer G., et al.
Publicado: (2018)

Contribution of intestinal triglyceride-rich lipoproteins to residual atherosclerotic cardiovascular disease risk in individuals with type 2 diabetes on statin therapy
por: Taskinen, Marja-Riitta, et al.
Publicado: (2023)

Cardiovascular Disease and Coronavirus Disease 2019: Epidemiology, Management, and Prevention
por: Ishigami, Junichi, et al.
Publicado: (2021)

Cardiovascular Imaging for the Primary Prevention of Atherosclerotic Cardiovascular Disease Events
por: Weber, Lauren A., et al.
Publicado: (2015)

Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease
por: Shapiro, Michael D., et al.
Publicado: (2017)

PA32540 for the secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers
por: Duffy, Danielle, et al.
Publicado: (2014)

Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease
por: Tada, Hayato, et al.
Publicado: (2019)

Is Lipoprotein(a) the Most Important Predictor of Residual Atherosclerotic Cardiovascular Disease Risk?
por: Wong, Nathan D.
Publicado: (2022)

Postprandial Hyperlipidemia and Remnant Lipoproteins
por: Masuda, Daisaku, et al.
Publicado: (2017)

Apolipoprotein B, Non-HDL Cholesterol, and LDL Cholesterol as Markers for Atherosclerotic Cardiovascular Disease Risk Assessment
por: Yun, Yeo-Min
Publicado: (2023)

Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran)
por: Sinning, David, et al.
Publicado: (2020)

Lipoprotein(a), Interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: Is there an association?
por: Makris, Anastasios, et al.
Publicado: (2023)

Lipoproteins, Cholesterol, and Atherosclerotic Cardiovascular Disease in East Asians and Europeans
por: Doi, Takahito, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mt9uaach9ek56mir60jnil30rt